Discovery of new treatment for pancreatic cancer

As reported by the BBC, Cancer Research funded scientists have identified a previously unknown faulty gene that appears to play a key role in some aggressive forms of pancreatic cancer.

A study published in the journal Nature, showed that a gene was being switched off in the cancerous cells. Scientists from Cancer Research UK’s Cambridge Research Institute and the Wellcome Trust Sanger Institute said drugs were already being tested which had the potential to turn the gene back on, to stop the spread of the cancer.

Currently around 8000 people in the UK are diagnosed with pancreatic cancer every year and fewer than one in five patients survive their disease for a year or more

Dr Julie Sharp, Cancer Research UK’s senior science information manager, said: “These results raise the possibility that a class of promising new cancer drugs may be effective at treating some pancreatic cancers.”

Click here to see our latest clinical roles

Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates

Posted in Industry News, NewsTagged in , , , , , , , , , , , , ,

Our Latest Clinical Jobs in this Week – 30/04/2012

Here is a list of the latest  clinical jobs that the Consultants here at CK Clinical have had in this week:

Clinical Project Physician – Oncology – South East

Regulatory Affairs Manager – Home Counties

Team Lead Pharmacovigilance Physician – South East

Director Clinical Developemnt – Oncology – South East

Head Of Medical Affairs – Surrey

Project Coordinator – Medical Affairs – Berkshire

Senior Pharmacovigilance Executive – Buckinghamshire

CRA Manager for Eastern Europe – Home Counties

Director of Regulatory Affairs – London

Clinical Project Physician – Oncology – Buckinghamshire

Register your CV

Click here to register your CV with CK Clinical.

Once registered, one of our specialist Pharmaceutical Recruitment Consultants will be in contact to confidentially discuss your requirements and any relevant pharmaceutical jobs we are recruiting for.

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , ,

Senior Pharmacovigilance Executive Buckinghamshire

Hendre Moolman at CK Clinical is looking for a Senior Pharmacovigilance Executive to join a large pharmaceutical company in Buckinghamshire.

The job:

As a Senior Pharmacovigilance Executive will work within the Medical Affairs Department and report to the Medical Affairs Manager. The main focus of your role would be to maintain and develop the drug safety processes, delivering a drug safety service for the company’s UK licensed and investigational products. One of the main challenges in this role would be to coordinate multiple tasks with tight deadlines. You will have proven Drug Safety experience with a life science degree.

Key responsibilities:

As a Senior Pharmacovigilance Executive your key responsibilities will be to: 

  • Perform the activities detailed in the Pharmacovigilance Agreement between Drug Safety Department, Head Office and the UK office
  • Your duties will include handling of individual case safety reports (ICSRs), implementing the UK quality system, carrying out literature searches as required
  • You will be doing training, compliance reporting, reviewing external agreements relating to drug safety and notifying updates to company core safety information
  • Ensure the accurate entry of drug safety case data arising from spontaneous or clinical trial reports
  • Liaise with the UK Medical Information personnel (or contractors) and Clinical Research personnel, external healthcare professionals, consumers or the MHRA to obtain available drug safety case information
  • Ensure that individual and aggregated safety reports are submitted within the required timelines to the relevant recipients and that a record of reporting compliance is forwarded to the QPPV as detailed in the Pharmacovigilance Agreement
  • Keep up-to-date with changes and developments in pharmacovigilance legislation and guidelines and the company’s internal procedures
  • Ensure that drug safety processes in the UK meet the current requirements for good pharmacovigilance practice
  • Develop and deliver drug safety training programmes relevant to all UK personnel who may be in receipt of drug safety information or perform functions related to drug safety.
  • Keep a record of drug safety training carried out by UK personnel and ensure that repeat or updated training is carried out at appropriate intervals
  • Maintain electronic and paper filing and archiving system suitable for the storage of source documents relating to drug safety case records
  • Foster good relations with Drug Safety personnel at Head Office

Qualifications & Experience:

The successful candidate for this Senior Pharmacovigilance Executive role will have the following qualifications and skills:

  • Life science, Healthcare degree, Pharmacist or Nurse
  • You must be a natural team player with the personal qualities to relate well to people at all levels.
  • Proven relevant industry experience within pharmacovigilance /drug safety

How to apply:

Apply online now

For more information or to apply for this Senior Pharmacovigilance Executive role please contact Hendre Moolman on 01438 870 023 or email hmoolman@ckclinical.co.uk.  Please quote reference CL24169 in all correspondence

Are you looking for a new job in the pharmaceutical industry? Click here to see our latest pharmacovigilance jobs.

Posted in Industry News, Job of the Week, NewsTagged in , , , , , , , , , , ,

Amgen acquires Turkish drug maker for $700 Million

Reuters reported that Biotechnology giant Amgen are set to buy Mustafa Nevzat Pharmaceuticals for almost $700 million to expand in Amgens market share in Turkey, where economic growth is boosting demand for medicines.

Mustafa Nevzat Pharmaceuticals (MN) is the leading supplier of pharmaceuticals to the hospital sector and a major supplier of injectable medicines in Turkey. It also has a successful and fast growing export business. Sales of pharmaceuticals are growing faster in emerging markets than in Europe and the United States, making them attractive to companies like Amgen.  Amgen’s focus on Turkey and the surrounding region is part of a broad international expansion strategy,” the company said in the statement.

The deal will give Amgen a platform for its own medicines in the fast-growing region, as well as providing scope to diversify and expand its product range as it loses exclusivity over its existing top-selling medicines.

Robert A. Bradway, president and chief operating officer at Amgen “Amgen is dedicated to making our innovative medicines available to patients in major markets around the world….Together with MN’s staff and management team, we plan to grow our business with high quality and innovative medicines in Turkey and the surrounding region.”

Are you looking for a new job in the biotechnology? Click here to see our latest jobs now

Posted in Industry News, NewsTagged in , , , , , , , , , , ,

AstraZeneca to buy Ardea Biosciences for £781m

The Independent reported that the British drug maker AstraZeneca has agreed a $1.26bn (£781m) deal to buy San Diego firm Ardea Biosciences.

AstraZeneca which is the UK 2nd biggest drug developer is currently looking for new products, acquiring Ardea also means that Astra Zeneca gains a drug called Lesinurad,

Ardea, California-based biotechnology company focused on the development of small-molecule therapeutics. Ardea’s top drug  Lesinurad  is currently in Phase III development as a potential treatment for the chronic management of hyperuricaemia in patients with gout. This disease is expected to affect almost 17 million people by 2019.

David Brennan, AstraZeneca’s chief executive, said: This attractive Phase III programme is an excellent opportunity to leverage AstraZeneca’s global specialty and primary care sales and marketing capabilities…..The Ardea team has done a great job developing Lesinurad along with a promising next-generation gout programme. These compounds have real potential to benefit patients.”

Click here to see our clinical roles in the UK and Europe

Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates

Posted in Industry News, NewsTagged in , , , , , , , , ,

Disappointment as NICE turns down Roche’s breast cancer drug

Pharmatimes reported that NICE have turned down Roche’s Avastin for patients with advanced breast cancer in a draft because of uncertainties over the drug’s survival and costing’s. Roche however say this drug could make a real difference to cancer patients.

NICE said despite clinical evidence showing that the drug is able to increase progression-free survival by just under three months compared with capecitabine alone, its effect on overall survival is less clear.. NICE’s appraisal committee concluded that they could not recommend the treatment as an effective use of NHS resources

Basel-based Roche said the draft guidance wasn’t the final recommendation from NICE  in this setting and that it will respond to the draft guidance as per NICE’s process.

Roche said “Avastin in combination with [chemotherapy drug] capecitabine is an important treatment option for women with breast cancer….In a subgroup analysis of women treated with a taxane when their disease was at an early stage, progression-free survival more than doubled from 4.2 months to 8.7 months compared to those treated capecitabine alone.”

Pharmatimes reported that this news will certainly disappoint   thousands of patients suffering from the condition, who will no doubt be hoping that additional evidence will be submitted during the current consultation period to overturn the decision.

Click here to see our latest pharmaceutical jobs!

Posted in Industry News, NewsTagged in , , , , , , , , , ,

What it’s like to work in Pharmaceuticals

CK Clinical, a leading Pharmaceutical recruitment consultancy have interviewed a number of professionals currently working in the Pharmaceutical Industry.

So, if you are interested in working in the Pharmaceutical Industry or are looking to change career paths within the industry, please click on the links below to find out what’s like to work within these various disciplines:

 

Register your CV

Click here to register your CV with us.

Once registered, one of our specialist Pharmaceutical Recruitment Consultants will be in contact to discuss your requirements and any pharmaceutical jobs which may be of interest to you.

Search our Pharmaceutical Jobs

Click here to search and apply for our current Pharmaceutical jobs in the UK and EU.

Contact Us

For more information regarding jobs in the UK and EU Pharmaceutical Industry, please contact CK Clinical on +44 (0)1438 743 047 or email info@ckclinical.co.uk.

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , , , , , , , ,

A new prostrate cancer treatment could remove the disease with fewer side effects

The Guardian reported that a study has revealed that a new treatment for prostate cancer could remove the disease from nine in ten men without debilitating side effects, leading to new hope for tens of thousands of men.

Researchers at UCL have conducted a small study of focal therapy which shows a dramatic fall in rates of incontinence and other problems after treatment. The study was the first to use an experimental treatment known as HIFU (high-intensity focused ultrasound) to treat areas of cancer that are only a few millimetres in size, a technique known as focal therapy.

Dr Hashim Ahmed, who led the study at University College London Hospitals NHS Foundation Trust and UCL, said: “Our results are very encouraging. We’re optimistic that men diagnosed with prostate cancer may soon be able to undergo a day case surgical procedure, which can be safely repeated once or twice, to treat their condition with very few side-effects. That could mean a significant improvement in their quality of life.

Click here to see our latest clinical research jobs

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , ,

Quintiles Named Best CRO In Vaccine Excellence Awards 2012

Pharmiweb reported that Quintiles has been named best Clinical Research Organization (CRO) in the Vaccine Industry Excellence (ViE) Awards 2012.

The awards recognize and celebrate the leaders, innovators and pioneers in the vaccines industry.  The awards were  presented at the World Vaccine Congress in Washington, D.C.

Customers voted for their preferred CRO prior to the World Vaccine Congress and a judging panel then made its selection based on a set criteria.

Dr. Ellen Vigdorth, VP Allergy, Respiratory, Infectious Diseases and Vaccines. “This is a great honor to be recognized as the Best CRO at the World Vaccine Congress…It is a huge achievement and underscores our commitment to the development of quality vaccines and anti-infective products.”

Are you looking for a new job in the clinical research industry? Click here to see our most recent clinical research jobs!

viagra

Posted in Industry News, News, UncategorizedTagged in , , , , , , , , , , , , ,

Takeda forms drug discovery partnership with SGC

As reported by the Pharmaceutical Business Review, the Japanese pharmaceutical company, Takeda Pharmaceuticalshas formed a drug discovery alliance with Structural Genomics Consortium (SGC).

The SGC is a not-for-profit, public-private partnership which supports the discovery of medicines through open access research. They focus on determining the three dimensional structure of human proteins which are targets for drug discovery.

The SGC have released the structures of over 1,200 proteins with implications to the development of new therapies for cancer, diabetes, obesity and psychiatric disorders. As well as their recent funding from Takeda, the SGC is also funded by the Canadian Institute for Health Research, CFI, Genome Canada, the Ontario’s MEDI and the Wellcome Trust.

By forming an alliance with the SGC, Takeda are able promote their drug discovery research by accessing new research. In addition, the SGC have benefitted aswell by raising their funds to $50m.

SGC Canada chief executive Aled Edwards said: “This is a strong endorsement of a novel business model, which relies on collaboration to share the risks of early-stage research, and reduce costs of drug discovery so we can get effective new medicines to market faster, and into the hands of physicians and patients sooner.”

Click here to search our current pharmaceutical jobs online now.

Posted in Industry News, NewsTagged in